Reversible	reversible	O	O	O	O
cerebral	cerebral	O	O	OTHERS	I
lesions	lesions	O	O	OTHERS	I
associated	associated	O	O	O	O
with	with	O	O	O	O
tiazofurin	tiazofurin	O	O	OTHERS	I
usage	usage	O	O	O	O
:	:	O	O	O	O
MR	mr	O	DISEASE	OTHERS	I
demonstration	demonstration	O	O	O	O
.	.	O	O	O	O

Tiazofurin	tiazofurin	O	O	OTHERS	I
is	is	O	O	O	O
an	an	O	O	O	O
experimental	experimental	O	O	O	O
chemotherapeutic	chemotherapeutic	O	O	O	O
agent	agent	O	O	O	O
currently	currently	O	O	O	O
undergoing	undergoing	O	O	O	O
clinical	clinical	O	O	O	O
evaluation	evaluation	O	O	O	O
.	.	O	O	O	O

We	we	O	O	O	O
report	report	O	O	O	O
our	our	O	O	O	O
results	results	O	O	O	O
with	with	O	O	O	O
magnetic	magnetic	O	O	O	O
resonance	resonance	O	O	O	O
(	(	O	O	O	O
MR	mr	O	DISEASE	OTHERS	I
)	)	O	O	O	O
in	in	O	O	O	O
demonstrating	demonstrating	O	O	O	O
reversible	reversible	O	O	O	O
cerebral	cerebral	O	O	OTHERS	I
abnormalities	abnormalities	O	O	OTHERS	I
concurrent	concurrent	O	O	O	O
with	with	O	O	O	O
the	the	O	O	O	O
use	use	O	O	O	O
of	of	O	O	O	O
this	this	O	O	O	O
drug	drug	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
abnormalities	abnormalities	O	O	O	O
on	on	O	O	O	O
MR	mr	O	DISEASE	OTHERS	I
were	were	O	O	O	O
correlated	correlated	O	O	O	O
with	with	O	O	O	O
findings	findings	O	O	O	O
on	on	O	O	O	O
CT	ct	O	O	O	O
as	as	O	O	O	O
well	well	O	O	O	O
as	as	O	O	O	O
with	with	O	O	O	O
cerebral	cerebral	O	O	O	O
angiography	angiography	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
utility	utility	O	O	O	O
of	of	O	O	O	O
MR	mr	O	DISEASE	OTHERS	I
in	in	O	O	O	O
the	the	O	O	O	O
evaluation	evaluation	O	O	O	O
of	of	O	O	O	O
patients	patients	O	O	O	O
receiving	receiving	O	O	O	O
this	this	O	O	O	O
new	new	O	O	O	O
agent	agent	O	O	O	O
is	is	O	O	O	O
illustrated	illustrated	O	O	O	O
.	.	O	O	O	O

